201 related articles for article (PubMed ID: 35342356)
21. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Domingo-Domènech J; Pippa R; Tápia M; Gascón P; Bachs O; Bosch M
Breast Cancer Res Treat; 2008 Nov; 112(1):53-62. PubMed ID: 18064564
[TBL] [Abstract][Full Text] [Related]
22. Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer.
Zhao P; Sun J; Huang X; Zhang X; Liu X; Liu R; Du G; Gan W; Yang C; Tang Y; Chen C; Jiang D
Int J Biol Sci; 2023; 19(6):1861-1874. PubMed ID: 37063424
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
[TBL] [Abstract][Full Text] [Related]
24. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
25. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
26. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
27. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
[TBL] [Abstract][Full Text] [Related]
29. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
Yang H; Lan P; Hou Z; Guan Y; Zhang J; Xu W; Tian Z; Zhang C
Br J Cancer; 2015 Jan; 112(1):112-21. PubMed ID: 25393367
[TBL] [Abstract][Full Text] [Related]
31. REST is a novel prognostic factor and therapeutic target for medulloblastoma.
Taylor P; Fangusaro J; Rajaram V; Goldman S; Helenowski IB; MacDonald T; Hasselblatt M; Riedemann L; Laureano A; Cooper L; Gopalakrishnan V
Mol Cancer Ther; 2012 Aug; 11(8):1713-1723. PubMed ID: 22848092
[TBL] [Abstract][Full Text] [Related]
32. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis.
Zhao D; Zhi X; Zhou Z; Chen C
Carcinogenesis; 2012 Jan; 33(1):59-67. PubMed ID: 22045023
[TBL] [Abstract][Full Text] [Related]
33. Krüppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1.
Zheng HQ; Zhou Z; Huang J; Chaudhury L; Dong JT; Chen C
Oncogene; 2009 Oct; 28(42):3702-13. PubMed ID: 19668233
[TBL] [Abstract][Full Text] [Related]
34. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
[TBL] [Abstract][Full Text] [Related]
36. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA).
Henderson C; Mizzau M; Paroni G; Maestro R; Schneider C; Brancolini C
J Biol Chem; 2003 Apr; 278(14):12579-89. PubMed ID: 12556448
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
Yamaguchi H; Chen CT; Chou CK; Pal A; Bornmann W; Hortobagyi GN; Hung MC
Oncogene; 2010 Oct; 29(41):5619-29. PubMed ID: 20676141
[TBL] [Abstract][Full Text] [Related]
38. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
39. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
Hutt DM; Roth DM; Vignaud H; Cullin C; Bouchecareilh M
PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
[TBL] [Abstract][Full Text] [Related]
40. Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
Chiaradonna F; Barozzi I; Miccolo C; Bucci G; Palorini R; Fornasari L; Botrugno OA; Pruneri G; Masullo M; Passafaro A; Galimberti VE; Fantin VR; Richon VM; Pece S; Viale G; Di Fiore PP; Draetta G; Pelicci PG; Minucci S; Chiocca S
Antioxid Redox Signal; 2015 Jul; 23(1):15-29. PubMed ID: 25897982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
